Evaluation of the oxygen delivery ability of PEG-hemoglobin in Sprague-Dawley rats during hemodilution

被引:9
作者
Conover, C [1 ]
Linberg, R [1 ]
Lejeune, L [1 ]
Gilbert, C [1 ]
Shum, K [1 ]
Shorr, RGL [1 ]
机构
[1] Enzon Inc, Res & Dev, Formulat Toxicol Dept, Piscataway, NJ 08854 USA
来源
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY | 1998年 / 26卷 / 02期
关键词
D O I
10.3109/10731199809119778
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Polyethylene glycol (PEG) conjugation allows bovine hemoglobin (Hb) to retain its oxygen delivery capability while increasing its plasma expansion capacity. To determine whether PEG-Hb's ability to sustain life is due to its oxygen delivery capability rather than its plasma expansion capacity, Sprague-Dawley rats were exchange-transfused up to an 85 % hematocrit reduction with either PEG-Hb, PEG-50%-methemoglobin (PEG-mHb), PEG-carbon monoxide hemoglobin (PEG-COHb) or PEG-human serum albumin (PEG-HSA). Survival and respiratory rates were monitored during the exchange transfusion, at five minutes, 24 hours and 48 hours post operative. Rats surviving 14 days were evaluated for hematology, blood chemistry and histopathology. Rats infused with PEG-Hb had a survival rate of 100% during the transfusion and 79% at 24 hours, as compared to 24 hour survival rates of 30% for PEG-mHb, and 0% for both PEG-COHb and PEG-HSA. PEG-Hb treated rats that survived the 2 week observation period had normal hematological and blood chemistry levels and no significant morphological effects. Therefore, this study demonstrates that PEG-Hb can sustain life while similar plasma expansion agents with less oxygen delivery capability are not as effective.
引用
收藏
页码:199 / 212
页数:14
相关论文
共 28 条
[1]   EFFECTS OF DEXTRAN ON LYSOSOMAL ULTRASTRUCTURE AND PROTEIN DIGESTION IN RENAL PROXIMAL TUBULE [J].
CHRISTENSEN, EI ;
MAUNSBACH, AB .
KIDNEY INTERNATIONAL, 1979, 16 (03) :301-311
[2]   Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat [J].
Conover, C ;
Lejeune, L ;
Linberg, R ;
Shum, K ;
Shorr, RGL .
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY, 1996, 24 (06) :599-611
[3]  
CONOVER C, 1997, IN PRESS ART ORGANS
[4]  
Conover CD, 1996, J INVEST MED, V44, P238
[5]  
DALMEIDA M, 1996, ARTIF CELL BLOOD SUB, V24, P299
[6]  
DEVENUTO F, 1982, SURG GYNECOL OBSTET, V155, P342
[7]  
DJORDJEVICH L, 1980, EXP HEMATOL, V8, P584
[8]  
ENGBERG A, 1976, ACTA CHIR SCAND, V142, P172
[9]  
ER S, 1996, ARTIF CELL BLOOD SUB, V24, P435
[10]  
ERICSSON JL, 1965, LAB INVEST, V14, P1